Trial Profile
Effect of Anti-IgE in Non-Allergic Asthma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2021
Price :
$35
*
At a glance
- Drugs Omalizumab (Primary)
- Indications Asthma
- Focus Biomarker; Pharmacodynamics
- 27 Jul 2017 Status changed from recruiting to discontinued.
- 02 Mar 2010 Results presented at the 66th Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 27 Nov 2005 New trial record.